Sector News

CEO of Novo Nordisk's biggest shareholder steps down

February 15, 2016
Life sciences

(Reuters) – Novo A/S, the parent company behind the world’s largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month.

Kolding, 56, has previously served as chief executive of Denmark’s largest bank, Danske Bank, and the world’s largest container shipping company, Maersk Line. He has been in the Novo job less than two years.

Aside from its shares in Novo Nordisk and top industrial enzyme maker Novozymes, Novo A/S has billions invested in both Danish and international life science companies.

“The board has concluded that having a CEO with a different profile to that of Eivind Kolding will be required in the long term,” chairman of the board Steen Scheibye said.

Novo said the hunt for a replacement has begun, but gave no further details. Scheibye becomes acting chief executive when Kolding leaves. ($1 = 6.6383 Danish crowns) (Reporting by Annabella Pultz Nielsen; Editing by Greg Mahlich)

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend